Merck & Co., On Behalf Of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Inc., Announces Results Of Tender Offer For Cubist’s 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 And 1.875% Convertible Senior Notes Due 20

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced the results of its tender offer (the “Convertible Notes Tender Offer”) pursuant to which each holder of Cubist’s 2.50% Convertible Senior Notes due 2017 (the “2017 Convertible Notes”), 1.125% Convertible Senior Notes due 2018 (the “2018 Convertible Notes”) and 1.875% Convertible Senior Notes due 2020 (the “2020 Convertible Notes” and together with the 2017 Convertible Notes and 2018 Convertible Notes, the “Convertible Notes”) had the right (the “Fundamental Change Repurchase Right”), at such holder’s option, to require Cubist to repurchase for cash all of such holder’s Convertible Notes, or any portion of the principal amount thereof that is equal to $1,000 or an integral multiple of $1,000 principal amount, on February 23, 2015. The Fundamental Change Repurchase Right expired at the end of the day, immediately after 11:59 p.m., Eastern time, on February 19, 2015 (the “Fundamental Change Expiration Time”), and was not extended. Cubist has been advised by The Bank of New York Mellon Trust Company, N.A., the Paying Agent and Conversion Agent for the Convertible Notes Tender Offer, and Mackenzie Partners, the Information Agent for the Convertible Notes Tender Offer, that none of the Notes were validly surrendered for repurchase prior to the Fundamental Change Expiration Time.

Help employers find you! Check out all the jobs and post your resume.